文献速递造血干细胞移植与细胞治疗

单倍体造血干细胞移植中序贯输注间充质干细胞预防移植物抗宿主病:一项开放标签、多中心、随机对照临床试验

Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled Clinical Trial.
PubMed 文献 · J Clin Oncol · 2025-04-15

这项开放标签、多中心、随机对照试验评估了单倍体造血干细胞移植(haplo-HSCT)后3个月内序贯输注脐带来源间充质干细胞(UC-MSC)预防移植物抗宿主病(GVHD)的疗效与安全性。共纳入192例合格受试者,随机分为MSC组和对照组。结果显示MSC组严重慢性GVHD和所有级别慢性GVHD的2年累积发生率均低于对照组,急性GVHD累积发生率显著降低,3年无GVHD无复发生存(GRFS)率显著提高。

要点

  • 序贯输注UC-MSC可降低haplo-HSCT后严重慢性GVHD和所有级别慢性GVHD的2年累积发生率。
  • MSC组1至4级、2至4级和3至4级急性GVHD累积发生率均显著降低(均P<.001)。
  • MSC组3年GRFS率为62.4%,显著高于对照组的32.0%(HR 0.34,P<.001)。

核心结论

  • 研究结果表明,haplo-HSCT后3个月内序贯输注MSC可显著降低慢性GVHD和急性GVHD的发生率及严重程度,表现为患者GRFS率更优。

研究设计与样本

  • 开放标签、多中心、随机对照临床试验,在中国三个移植中心纳入192例年龄18至60岁接受haplo-HSCT的合格受试者,随机分配至MSC组和对照组。
  • MSC组干预方案为:第0天开始前4小时输注1×10^6/kg,移植后第一个月每周一次,第二个月每两周一次,第三个月一次,共八剂。
  • 主要终点为严重慢性GVHD的2年累积发生率。

主要发现

  • MSC组严重慢性GVHD的2年累积发生率低于对照组(P=.033),所有级别慢性GVHD的2年累积发生率也低于对照组(P=.022)。
  • MSC组1至4级、2至4级和3至4级急性GVHD累积发生率均显著降低(均P<.001)。
  • MSC组3年GRFS率为62.4%,显著高于对照组的32.0%(HR 0.34,P<.001)。
  • MSC输注未影响复发累积发生率(P=.34)和非复发死亡率(P=.45)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this open-label, multicenter, randomized controlled trial was to determine the efficacy and safety of sequential umbilical cord-derived mesenchymal stem cell (UC-MSC) infusion for graft-versus-host disease (GVHD) prevention within 3 months of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). METHODS: This open-label study evaluated UC-MSC infusion (administer 1 × 106/kg 4 hours before the commencement of day 0, once weekly for the first month after transplantation, once every 2 weeks for the second month, and once during the third month, totaling eight doses). The primary end point was the 2-year cumulative incidence of severe chronic GVHD (cGVHD). RESULTS: In the primary analysis, 192 qualified participants between age 18 and 60 years with haplo-HSCT in three transplant centers in China were enrolled and randomly assigned to the MSC and control groups. In the primary analysis, the estimated 2-year cumulative incidence of severe cGVHD and all grades of cGVHD was lower in the MSC group than in the control group (P = .033 and P = .022). The cumulative incidence of grade 1 to 4, 2 to 4, and 3 to 4 acute GVHD (aGVHD) in patients in the MSC group significantly decreased (all P < .001). The 3-year GVHD-free and relapse-free survival (GRFS) rate in the MSC group was 62.4%, which was significantly higher than that in the control group (32.0%, hazard ratio [HR], 0.34, P < .001). MSC infusion did not influence the cumulative incidence of relapse (P = .34) and nonrelapse mortality (P = .45). CONCLUSION: Our findings suggest that sequential infusion of MSCs within 3 months after haplo-HSCT significantly reduced both the incidence and severity of cGVHD and aGVHD, manifesting as a better GRFS rate for patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yao H, Huang R, Fu H, et al. Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Randomized Controlled Clinical Trial. J Clin Oncol. 2025. PMID: 40233291. doi:10.1200/JCO-24-02119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。